Simon Moussaud
YOU?
Author Swipe
View article: TMIC-62. Astrocyte-expressed FASN as a novel candidate drug target for glioblastoma
TMIC-62. Astrocyte-expressed FASN as a novel candidate drug target for glioblastoma Open
BACKGROUND Glioblastoma (GBM) is an aggressive cancer requiring deeper understanding and new therapeutic approaches. The tumoral microenvironment guide cancer cell progression. Our previous studies demonstrated that astrocytes (ACs) enhanc…
View article: DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT
DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT Open
View article: High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in sonic hedgehog-medulloblastoma
High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in sonic hedgehog-medulloblastoma Open
Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Current treatments have increased overall survival but can lead to devastating side effects and late complications in survivors, emphasizing the …
View article: High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma
High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in SHH-medulloblastoma Open
Background Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Current treatments have increased overall survival but can lead to devastating side effects and late complications in survivors, emphasizing the …
View article: Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth
Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth Open
Background High-grade gliomas are malignant brain tumors characterized by aggressiveness and resistance to chemotherapy. Prognosis remains dismal, highlighting the need to identify novel molecular dependencies and targets. Ribosome biogene…
View article: Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice
Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice Open
Liver-generated plasma apolipoprotein E (apoE) does not enter the brain but nonetheless correlates with Alzheimer’s disease (AD) risk and AD biomarker levels. Carriers of APOE ε4, the strongest genetic AD risk factor, exhibit lower plasma …
View article: Effects of a liver <i>APOEε4</i>‐genotype on synaptic integrity, gliosis and insulin signaling in the brain
Effects of a liver <i>APOEε4</i>‐genotype on synaptic integrity, gliosis and insulin signaling in the brain Open
Background APOEε4 is the strongest genetic risk factor for AD[1]. Although plasma apoE does not cross the blood‐brain‐barrier[2], altered plasma apoE levels have been linked to increased risk of AD[3] and to unfavorable CSF Aβ42 and tau le…
View article: Amyloid‐beta 1‐40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro
Amyloid‐beta 1‐40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro Open
Summary The population of brain pericytes, a cell type important for vessel stability and blood brain barrier function, has recently been shown altered in patients with Alzheimer's disease ( AD ). The underlying reason for this alteration …
View article: Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease Open
View article: Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein
Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein Open
Misfolding and aggregation of alpha-synuclein (αsyn) resulting in cytotoxicity is a hallmark of Parkinson's disease (PD) and related synucleinopathies. The recent body of evidence indicates that αsyn can be released from neuronal cells by …
View article: Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons
Proaggregant nuclear factor(s) trigger rapid formation of α-synuclein aggregates in apoptotic neurons Open
View article: A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo
A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo Open
Alpha synuclein (αsyn) aggregates are associated with the pathogenesis of Parkinson's disease and others related disorders. Although modulation of αsyn aggregation is an attractive therapeutic target, new powerful methodologies are despera…
View article: Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies
Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies Open
The application of the strategy described herein to monitor α-synuclein oligomer formation in living cells with high throughput will facilitate drug discovery efforts for disease-modifying therapies against synucleinopathies and other prot…